Key Highlights
- Earnings per share of USD 0.32 beat the USD 0.26 estimate, while Revenue of USD 18.68 million fell slightly short.
- Revenue rose 10.6%, and Operating Income grew 30.7% to USD 3.5 million, an 18.7% operating margin.
- Gross margin was 80.0% against 78.1%, and home care revenue grew 17.6% to USD 17.5 million.
- Cash was USD 15.9 million with no debt, and 87% of covered lives in the United States were under contract.
Electromed (NYSE American:ELMD), a maker of airway clearance therapy systems, reported fiscal first quarter 2027 earnings of USD 0.32 per share, above the USD 0.26 estimate and up 28% from USD 0.25 a year earlier. Revenue of USD 18.68 million was slightly below the USD 18.85 million estimate. The quarter ended September 30, 2026, and the company's fiscal year ends in June.
Revenue rose 10.6% from USD 16.9 million. Management said this was the 16th consecutive quarter of year-over-year increases in both revenue and operating income. Net Income was USD 2.8 million against USD 2.1 million.
Channels and Sales Productivity
Home care revenue rose USD 2.6 million, or 17.6%, to USD 17.5 million, which management attributed to additional sales representatives and improving productivity. Annualized home care revenue per weighted average direct sales representative was USD 1,109,000, just above the midpoint of its fiscal 2027 target range of USD 1,050,000 to USD 1,150,000.
Hospital revenue fell 31.6% to USD 716,000, and homecare distributor revenue fell 55.9% to USD 366,000. Management linked the decline in non-home care revenue to elevated distributor inventory and lower hospital Capital sales against record hospital revenue a year earlier. The filing states amounts subject to capped installment payment arrangements were about 96% of net revenues in the home care channel, against 95%.
Margins and Balance Sheet
Gross profit was USD 14.9 million, or 80.0% of net revenue, against USD 13.2 million, or 78.1%. SG&A expenses were USD 11.2 million, up USD 0.9 million, or 8.6%. Operating income was USD 3.5 million against USD 2.7 million.
At September 30, 2026, the company had USD 15.9 million in cash, USD 30.3 million in Accounts Receivable and no debt, with Working Capital of USD 44.9 million and shareholders' Equity of USD 52.5 million. Cash decreased USD 4.6 million in the quarter.
Coverage, Digital Ordering and Leadership
Management said 87% of covered lives in the United States were under contract, reflecting eight new or expanded agreements covering nearly 500,000 additional lives. It said 48% of orders were submitted through its SmartOrder platform, and that those orders shipped about five days faster than fax-based orders. It also cited registry data indicating 58% of qualifying patients were not prescribed high frequency chest wall oscillation therapy despite meeting clinical criteria.
The chief executive said he expects to retire in April 2027, as previously announced. The filing's Legal Proceedings item states the company is not aware of undisclosed actual or threatened litigation, other than ordinary routine litigation, that would have a material adverse effect. The items to follow are sales representative productivity, non-home care channels, gross margin and the Leadership transition.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...